Epidermal growth factor, from gene organization to bedside

Zeng, Fenghua; Harris, Raymond C.

doi:10.1016/j.semcdb.2014.01.011

Cited by 169 publications

(139 citation statements)

References 153 publications

(179 reference statements)

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…EGF was originally identified by the Nobel laureate Dr. Stanley Cohen and his colleagues as the factor in a submaxillary gland extract that induced precocious eyelid opening and incisor eruption due to stimulation of epidermal growth and keratinization when injected into newborn mice (630). Work by Cohen and Graham Carpenter subsequently identified that EGF's actions were mediated by binding to and activation of EGFR.…”

Section: Introductionmentioning

confidence: 99%

Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease

Chen

Zeng

Forrester

et al. 2016

Physiological Reviews

Self Cite

220

156

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is the prototypical member of a family of membrane-associated intrinsic tyrosine kinase receptors, the ErbB family. EGFR is activated by multiple ligands, including EGF, transforming growth factor (TGF)-α, HB-EGF, betacellulin, amphiregulin, epiregulin, and epigen. EGFR is expressed in multiple organs and plays important roles in proliferation, survival, and differentiation in both development and normal physiology, as well as in pathophysiological conditions. In addition, EGFR transactivation underlies some important biologic consequences in response to many G protein-coupled receptor (GPCR) agonists. Aberrant EGFR activation is a significant factor in development and progression of multiple cancers, which has led to development of mechanism-based therapies with specific receptor antibodies and tyrosine kinase inhibitors. This review highlights the current knowledge about mechanisms and roles of EGFR in physiology and disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease

Chen

Zeng

Forrester

et al. 2016

Physiological Reviews

Self Cite

220

156

View full text Add to dashboard Cite

show abstract

“…222 To resolve the problems of in vivo gene delivery, Wolschek et al 223 synthesized PEGylated EGF-containing DNA/PEI complexes for HCC targeting. The study on 2 xenotransplantation models for human HCC showed that expression levels within the tumors were up to 97%-99% of the total transgene expression in vivo, which is two logs higher than levels in the major expressing organ, liver.…”

mentioning

confidence: 99%

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Li¹,

Zhang²,

Wang³

et al. 2016

IJN

118

View full text Add to dashboard Cite

“…Growth factors bind to specific receptors which present on cell surface and contain a tyrosine kinase domain in their C-terminus (7,8) .The epidermal growth factor family firmly interfere in implantation process .This family includes epidermal growth factor (EGF), amphiregulin (AR), heparin-binding epidermal growth factor (HB-EGF) and transforming growth factor alpha (TGFα) (9) . At implantation TGFα, HB-EGF and AR are expressed in the uterus; in particular, HB-EGF appears to be highly relevant to implantation.…”

Section: Issn: 2320-5407mentioning

confidence: 99%

Role of Heparin Binding Epidermal Growth Factor in the Serum and Follicular Fluid in Prediction of Pregnancy Outcome of Infertile Women With and Without Pcos.

Dujaily¹,

Kareem²,

Selman³

2017

IJAR

View full text Add to dashboard Cite

Background: Successful implantation requires an intricate succession of molecular and genetic interactions. The implantation process is controlled by number of molecules like ovarian hormones, cytokines and growth factors which play an important role in regulating embryo differentiation, invasion and adhesion. During this time any breach in the communication between the endometrium and the embryo leads to implantation failure. Aim of the study: to evaluate the role of Heparin binding epidermal growth factor (HB-EGF), measured in serum and follicular fluid in prediction of pregnancy outcome of infertile women with and without PCOS. Patients and methods: A convenient sample of 100 infertile women undergoing intracytoplasmic sperm injection (ICSI) were intentionally divided, according to the cause of infertility, into 50 infertile women with polycystic ovary syndrome (PCOS) and 50 infertile women without PCOS. Heparin binding epidermal growth factor was measured on early follicular phase of the cycle (CD2-3) and at the day of ovarian pick up. Results: Highly significant(P<0.001) increase were reported between PCOS and non-PCOS groups regarding estradiol (E 2 ) and HB-EGF levels in the serum follicular phase (day 2-3) and in the FF on day of ova pickup (OPU).In PCOS women , HBEGF in the serum of follicular phase and at day of OPU with its level in the FF at day of OPU were all significantly (P<0.05) higher in women with positive pregnancy outcome than those with negative pregnancy outcome. Conclusion: Serum HB-EGF level is more valuable in predicting pregnancy out come in infertile PCOS women than non-PCOS women, and that serum HB-EGF level is more helpful than follicular fluid HB-EGF level in predicting pregnancy outcome in infertile PCOS women.

show abstract

Epidermal growth factor, from gene organization to bedside

Cited by 169 publications

References 153 publications

Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease

Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Role of Heparin Binding Epidermal Growth Factor in the Serum and Follicular Fluid in Prediction of Pregnancy Outcome of Infertile Women With and Without Pcos.

Contact Info

Product

Resources

About